Supernus Pharmaceuticals, Inc. (SUPN)
-NasdaqGM 6.00 
0.16(2.74%) May 17, 4:00PM EDT|After Hours
:
6.00 0.00 (0.00%) May 17, 4:32PM EDT
| Prev Close: | 5.84 |
|---|
| Open: | 5.96 |
|---|
| Bid: | 5.85 x 1500 |
|---|
| Ask: | 6.22 x 600 |
|---|
| 1y Target Est: | 11.80 |
|---|
| Beta: | 4.434 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 5.81 - 6.09 |
|---|
| 52wk Range: | 4.30 - 16.68 |
|---|
| Volume: | 927,579 |
|---|
| Avg Vol (3m): | 446,032 |
|---|
| Market Cap: | 185.25M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.26 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 5 Stocks Setting Up to Break Outat TheStreet(Fri, May 17)
- SUPERNUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- 8 Stocks Under $10 Trending Sharply Higherat TheStreet(Tue, May 14)
- Narrower-than-Expected Loss at SupernusZacks(Tue, May 14)
- Supernus Pharmaceuticals Reports First Quarter 2013 Financial ResultsGlobeNewswire(Mon, May 13)
- SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsEDGAR Online(Mon, May 13)
- Q1 2013 Supernus Pharmaceuticals Earnings Release - After Market CloseCCBN(Mon, May 13)
- SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct FinEDGAR Online(Thu, May 9)
- Supernus Announces First Quarter 2013 Earnings Conference Call and WebcastGlobeNewswire(Mon, May 6)
- SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Mon, May 6)
- Supernus Announces Closing of $90 Million of 7.50% Convertible Senior Secured Notes Due 2019GlobeNewswire(Mon, May 6)
- Supernus Secures Financing For CNS Pipeline Developmentat Seeking Alpha(Sun, May 5)
- Generic Drug Pricing Pressure Remains in Western Europe, While Central and Eastern Europe, Latin America and Parts of Asia Eye Fairly Strong Growth in Generic DrugsWall Street Transcript(Thu, May 2)
- Supernus rebounds with call buyingoptionMONSTER(Mon, Apr 29)
- Supernus Prices Offering of $75 Million of 7.50% Convertible Senior Secured Notes Due 2019GlobeNewswire(Fri, Apr 26)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 127.07 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.46 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.68 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases.
View More